Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.

ABSTRACT:

Background

Development of live attenuated influenza vaccines (LAIV) against avian viruses with pandemic potential is an important public health strategy.

Methods and findings

We performed open-label trials to evaluate the safety, infectivity, and immunogenicity of H5N1 VN 2004 AA ca and H5N1 HK 2003 AA ca. Each of these vaccines contains a modified H5 hemagglutinin and unmodified N1 neuraminidase from the respective wild-type (wt) parent virus and the six internal protein gene segments of the A/Ann Arbor/6/60 cold-adapted (ca) master donor virus. The H5N1 VN 2004 AA ca vaccine virus was evaluated at dosages of 10(6.7) TCID(50) and 10(7.5) TCID(50), and the H5N1 HK 2003 AA ca vaccine was evaluated at a dosage of 10(7.5) TCID(50). Two doses were administered intranasally to he

SUBMITTER: Karron RA 

PROVIDER: S-EPMC4806665 | biostudies-literature | 2009 Aug

REPOSITORIES: biostudies-literature